UTILIZING A SMALL MOLECULE AND NANOPARTICLE FORMULATED STAT3 INHIBITOR TO STOP THE PROCESS OF TUMORIGENESIS AND TUMOR-MEDIATED IMMUNE SUPPRESSION IN A PHASE I/II CLINICAL TRIAL WITH UNIQUE CORRELATIVE BIOMARKERS OF POTENTIAL CLINICAL RESPONSE.

PIs: Amy Heimberger, M.D.
Professor, Neurosurgery
MD Anderson Cancer Center

Waldemar Priebe, M.Sc., Ph.D.
Professor, Experimental Therapeutics Department
MD Anderson Cancer Center

Charles A. Conrad, M.D.
Professor, Neuro-Oncology
MD Anderson Cancer Center